Vorapaxar in the secondary prevention of atherothrombosis

Expert Review of Cardiovascular Therapy

Volumn 13, Issue 12, 2015, Pages 1293-1305

  Tantry, Udaya S ^a   Liu, Fang ^a,b   Chen, Gailing ^a,c   Gurbel, Paul A ^a  

^a INOVA HEART AND VASCULAR INSTITUTE   (United States)

^b BEIJING HOSPITAL   (China)

^c CHINA JAPAN FRIENDSHIP HOSPITAL   (China)

Author keywords

Acute coronary syndrome; Platelet; Protease activated receptor 1; Thrombin; Vorapaxar

Indexed keywords

PROTEINASE ACTIVATED RECEPTOR 1; VORAPAXAR; ANTITHROMBOCYTIC AGENT; LACTONE; PYRIDINE DERIVATIVE;

ARTICLE; CEREBROVASCULAR ACCIDENT; CORONARY STENTING; DIABETES MELLITUS; DRUG APPROVAL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG METABOLISM; DRUG SCREENING; EX VIVO STUDY; FOOD AND DRUG ADMINISTRATION; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; IN VITRO STUDY; LONG TERM CARE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PHARMACODYNAMICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY PREVENTION; THROMBOSIS; THROMBOSIS PREVENTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); COMPLICATION; MYOCARDIAL ISCHEMIA; PATIENT SELECTION; PROCEDURES; RISK ASSESSMENT; STROKE; TREATMENT OUTCOME;

CLINICAL TRIALS AS TOPIC; HUMANS; LACTONES; MYOCARDIAL ISCHEMIA; OUTCOME AND PROCESS ASSESSMENT (HEALTH CARE); PATIENT SELECTION; PLATELET AGGREGATION INHIBITORS; PYRIDINES; RECEPTOR, PAR-1; RISK ASSESSMENT; SECONDARY PREVENTION; STROKE; THROMBOSIS;

EID: 84948574272     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.2015.1109447     Document Type: Article

References (45)

1. Gurbel PA, Kuliopulos A, Tantry US. G-protein-coupled receptors signaling pathways in new antiplatelet drug development. Arterioscler Thromb Vasc Biol. 2015; 35: 500-512.
2. Zhang P, Covic L, Kuliopulos A. Protease-activated receptors. In: Michelson AD, editor. Platelets. 3rd ed. San Diego (CA): Academic Press; 2013. p. 249-259.
3. Wiviott SD, Braunwald E, McCabe CH, et al. TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357: 2001-2015.
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009; 361: 1045-1057.
5. Silvain J, Collet JP, Nagaswami C, et al. Composition of coronary thrombus in acute myocardial infarction. J Am Coll Cardiol. 2011; 57: 1359-1367.
6. Yunoki K, Naruko T, Sugioka K, et al. Erythrocyte-rich thrombus aspirated from patients with ST-elevation myocardial infarction: association with oxidative stress and its impact on myocardial reperfusion. Eur Heart J. 2012; 33: 1480-1490.
7. Ardissino D, Merlini PA, Bauer KA, et al. Coagulation activation and long-term outcome in acute coronary syndromes. Blood. 2003; 102: 2731-2735.
8. Undas A, Szułdrzyński K, Brummel-Ziedins KE, et al. Systemic blood coagulation activation in acute coronary syndromes. Blood. 2009; 113: 2070-2078.
9. Skeppholm M, Kallner A, Malmqvist K, et al. Is fibrin formation and thrombin generation increased during and after an acute coronary syndrome? Thromb Res. 2011; 128: 483-489.
10. Rothberg MB, Celestin C, Fiore LD, et al. Warfarin plus aspirin after myocardial infarction or the acute coronary syndrome: meta-analysis with estimates of risk and benefit. Ann Intern Med. 2005; 143: 241-250.
11. Komócsi A, Vorobcsuk A, Kehl D, et al. Use of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials. Arch Intern Med. 2012; 172: 1537-1545.
12. Leger AJ, Jacques SL, Badar J, et al. Blocking the protease-activated receptor 1-4 heterodimer in platelet-mediated thrombosis. Circulation. 2006; 113: 1244-1254.
13. Gieseler F, Ungefroren H, Settmacher U, et al. Proteinase-activated receptors (PARs)-focus on receptor-receptor-interactions and their physiological and pathophysiological impact. Cell Commun Signal. 2013; 11: 86.
14. Ramachandran R, Noorbakhsh F, Defea K, et al. Targeting proteinase-activated receptors: therapeutic potential and challenges. Nat Rev Drug Discov. 2012; 11: 69-86.
15. Brass LF, Vassallo RR Jr, Belmonte E, et al. Structure and function of the human platelet thrombin receptor. Studies using monoclonal antibodies directed against a defined domain within the receptor N terminus. J Biol Chem. 1992; 267: 13795-13798.
16. Gurbel PA, Jeong YH, Tantry US. Vorapaxar: a novel protease-activated receptor-1 inhibitor. Expert Opin Investig Drugs. 2011; 20: 1445-1453.
17. Zhang P, Gruber A, Kasuda S, et al. Suppression of arterial thrombosis without affecting hemostatic parameters with a cell-penetrating PAR1 pepducin. Circulation. 2012; 126: 83-91.
18. FDA approves Zontivity to reduce the risk of heart attacks and stroke in high-risk patients [Internet; cited 2015 Oct 15]. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm396585.htm.
19. Zhang C, Srinivasan Y, Arlow DH, et al. High-resolution crystal structure of human protease-activated receptor 1. Nature. 2012; 492: 387-392.
20. Ghosal A, Lu X, Penner N, et al. Identification of human liver cytochrome P450 enzymes involved in the metabolism of SCH 530348 (vorapaxar), a potent oral thrombin protease-activated receptor 1 antagonist. Drug Metab Dispos. 2011; 39: 30-38.
21. Chackalamannil S, Wang Y, Greenlee WJ, et al. Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity. J Med Chem. 2008; 51: 3061-3064.
22. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for asymptomatic atherosclerosis trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA. 2010; 303: 841-848.
23. Hawes BE, Zhai Y, Hesk D, et al. In vitro pharmacological characterization of vorapaxar, a novel platelet thrombin receptor antagonist. Eur J Pharmacol. 2015; 762: 221-228.
24. Kosoglou T, Reyderman L, Tiessen RG, et al. Pharmacodynamics and pharmacokinetics of the novel PAR-1 antagonist vorapaxar (formerly SCH 530348) in healthy subjects. Eur J Clin Pharmacol. 2012; 68: 249-258.
25. Becker RC, Moliterno DJ, Jennings LK, et al. Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study. Lancet. 2009; 373: 919-928.
26. Cavender MA, Scirica BM, Bonaca MP, et al. Vorapaxar in patients with diabetes mellitus and previous myocardial infarction: findings from the thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 trial. Circulation. 2015; 131: 1047-1053.
27. Goto S, Yamaguchi T, Ikeda Y, et al. Safety and exploratory efficacy of the novel thrombin receptor (PAR-1) antagonist SCH530348 for non-ST-segment elevation acute coronary syndrome. J Atheroscler Thromb. 2010; 17: 156-164.
28. Tricoci P, Huang Z, Held C, et al. TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med. 2012; 366: 20-33.
29. Valgimigli M, Tricoci P, Huang Z, et al. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial). Am J Cardiol. 2014; 114: 665-673.
30. Cornel JH, Tricoci P, Lokhnygina Y, et al. Glycoprotein IIb/IIIa receptor inhibitors in combination with vorapaxar, a platelet thrombin receptor antagonist, among patients with non-st-segment elevation acute coronary syndromes (from the TRACER Trial). Am J Cardiol. 2015; 115: 1325-1332.
31. Held C, Tricoci P, Huang Z, et al. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial. Eur Heart J Acute Cardiovasc Care. 2014; 3: 246-256.
32. Whellan DJ, Tricoci P, Chen E, et al. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (thrombin receptor antagonist for clinical event reduction in acute coronary syndrome). J Am Coll Cardiol. 2014; 63: 1048-1057.
33. Jones WS, Tricoci P, Huang Z, et al. Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRACER). Am Heart J. 2014; 168: 588-596.
34. Tricoci P, Lokhnygina Y, Huang Z, et al. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial. Am Heart J. 2014; 168: 869-77.e1.
35. Mahaffey KW, Huang Z, Wallentin L, et al. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial). Am J Cardiol. 2014; 113: 936-944.
36. Morrow DA, Braunwald E, Bonaca MP, et al. TRA 2P-TIMI 50 Steering Committee and Investigators. Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med. 2012; 366: 1404-1413.
37. Bhatt DL, Flather MD, Hacke W, et al. CHARISMA investigators. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007; 49: 1982-1988.
38. Magnani G, Bonaca MP, Braunwald E, et al. Efficacy and safety of vorapaxar as approved for clinical use in the United States. J Am Heart Assoc. 2015; 4: e001505.
39. Scirica BM, Bonaca MP, Braunwald E, et al. TRA 2°P-TIMI 50 Steering Committee Investigators. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial. Lancet. 2012; 380: 1317-1324.
40. Bonaca MP, Scirica BM, Braunwald E, et al. Coronary stent thrombosis with vorapaxar versus placebo: results from the TRA 2° P-TIMI 50 trial. J Am Coll Cardiol. 2014; 64: 2309-2317.
41. Morrow DA, Alberts MJ, Mohr JP, et al. Thrombin receptor antagonist in secondary prevention of atherothrombotic ischemic events-TIMI 50 steering committee and investigators. efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke. 2013; 44: 691-698.
42. Bonaca MP, Scirica BM, Braunwald E, et al. New ischemic stroke and outcomes with vorapaxar versus placebo: results from the TRA 2 °P-TIMI 50 trial. J Am Coll Cardiol. 2014; 64: 2318-2326.
43. Alonso-Coello P, Bellmunt S, McGorrian C, et al. American college of chest physicians. antithrombotic therapy in peripheral artery disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012; 141 (2 Suppl): e669S-e690S.
44. 0P-TIMI 50. Circulation. 2013; 127: 1522-1529.
45. Zontivity [Internet; cited 2015 Oct 15]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002814/human-med-001839.jsp&mid=WC0b01ac058001d124.